Abstract
Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).
Original language | English |
---|---|
Pages (from-to) | 2601-13 |
Number of pages | 13 |
Journal | European Heart Journal |
Volume | 31 |
Issue number | 21 |
DOIs | |
Publication status | Published - Nov 2010 |
Keywords
- Acute Coronary Syndrome
- Administration, Oral
- Coronary Artery Disease
- Double-Blind Method
- Drug-Induced Liver Injury
- Female
- Hemorrhage
- Humans
- Imines
- Long QT Syndrome
- Male
- Middle Aged
- Platelet Aggregation Inhibitors
- Pyridines
- Receptor, PAR-1